Insulet: A Great Story Wearing a Litigation Ankle Monitor, Right Before Earnings

Here's the thing about Insulet nobody wants to say in polite analyst-note company: this is a genuinely excellent business trading like one, wrapped in a legal cloud, walking straight into an earnings print in two days. That's not a stock, that's a dare.

The good stuff is really good

Let's not undersell it. Q1 2026 revenue came in at $761.7 million, up 33.9% year-over-year — that's not a rounding-error beat, that's blowing through the top of guidance. Net income and operating cash flow nearly doubled. The customer base grew almost 25% year-over-year. In an industry where "durable double-digit growth" usually means 12-14%, Insulet is putting up numbers that look like a software company having a good quarter, except this is insulin pumps.

The product itself keeps getting better in ways that widen the moat rather than just patch it. The June rollout of Omnipod 5's algorithm enhancements — a new 100 mg/dL glucose target, smarter automation, and crucially, compatibility with Abbott's Libre 3 Plus sensor — is the kind of incremental-but-real improvement that keeps switching costs high and competitors chasing. And the type 2 diabetes ambition (EVOLUTION 2 data, a pivotal EVOLVE study targeted this year, 510(k) filing in 2027, launch in 2028) is the actual long-term thesis here: Omnipod stops being a type 1 franchise and becomes a much bigger platform play. That's the bull case in one sentence — this company is trying to 10x its addressable market while its current market is still compounding at 30%+.

Now the part that should make you nervous

There's a federal securities class action alleging manufacturing defects and misleading safety claims, with a lead plaintiff deadline of August 31. The FDA is on record acknowledging Insulet sent letters recommending certain pods be pulled from where they're used or sold. That is not background noise — that's the kind of thing that turns "device company with a great algorithm" into "device company defending itself in depositions" for the next 18 months. And UBS just walked its rating down from Buy to Neutral on July 28. When the sell-side starts trimming right as the litigation clock ticks, that's not a coincidence, that's a signal.

Then there's the valuation. At roughly $165 a share and a P/E near 38.5x, PODD is priced like nothing goes wrong. Consensus price targets cluster around $214 (with a scatter from $180 to $249), which on paper looks like 30% upside — except one source is still floating a stale $374 target from what appears to be an older, more optimistic vintage of Wall Street math. That gap between $214 and $374 tells you something important: analyst estimates on this name are noisy right now, and when the Street can't agree within spitting distance of itself, that's usually a sign the story is in transition, not consensus.

The immediate problem: earnings on Wednesday

Q2 results land August 5, with the Street looking for adjusted EPS around $1.38-$1.44, roughly 18% year-over-year growth. That's a deceleration narrative sitting right next to a 34% top-line quarter from Q1 — and at 38x earnings, the market has zero patience for deceleration. Combine that with an active lawsuit and a recent downgrade, and you've got a stock where the setup into earnings is genuinely two-sided: a beat-and-raise could reassert the growth story and shrug off the legal noise; a miss or cautious guide gets amplified by everything else sitting on the tape right now.

Where I land

I'm not bearish on the business — the Omnipod 5 ecosystem and the type 2 diabetes optionality are real, differentiated, and still early. But I'm not chasing this into an earnings print while a securities lawsuit is live and the multiple already assumes near-flawless execution. This is a "let the quarter happen" stock, not a "buy ahead of the print" stock. If Insulet delivers and the legal overhang stays contained, $165 looks cheap in hindsight. If it doesn't, the crowd priced at 38x earnings won't wait around to find out why.

Own the story. Just don't pretend the ankle monitor isn't there.